Lupin receives USFDA approval for Brimonidine Tartrate Ophthalmic Solution, 0.1%
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Subscribe To Our Newsletter & Stay Updated